The global cyclosporine market, valued at USD 4.22 billion in 2024, is projected to grow at a CAGR of 5.3% from 2025 to 2034. This growth is being driven by the strategic positioning of key countries and the evolving corporate strategies of leading global players. As demand for immunosuppressive therapies expands across transplant and autoimmune disease indications, the market is increasingly influenced by national policy impact, R&D leadership, and localized manufacturing capabilities. Countries such as the United States, Germany, and India are playing pivotal roles in shaping market dynamics through regulatory enforcemen